axovant
gene
therapies
receives
rare
pediatric
disease
designation
sandhoff
disease
new
york
globe
newswire
axovant
gene
therapies
nasdaq
axgt
company
developing
innovative
gene
therapies
neurological
diseases
today
announced
received
rare
pediatric
disease
designation
food
drug
administration
fda
gene
therapy
delivered
directly
central
nervous
system
development
gangliosidosis
also
known
sandhoff
disease
addition
rare
pediatric
disease
designation
orphan
drug
designation
odd
first
gene
therapy
administered
children
disease
thrilled
bring
one
step
closer
patients
need
rare
pediatric
disease
designation
potential
first
treatment
approved
sandhoff
disease
rare
fatal
pediatric
diseases
current
treatment
options
said
sean
bryan
senior
vice
president
regulatory
affairs
quality
axovant
expects
evaluate
registrational
clinical
trial
consists
stage
study
stage
efficacy
study
previously
axovant
reported
first
evidence
potential
disease
modification
disease
expanded
access
study
administering
investigational
gene
therapy
two
patients
infantile
type
disease
successfully
administered
patients
generally
date
serious
adverse
events
clinically
relevant
laboratory
abnormalities
related
therapy
gangliosidosis
also
known
sandhoff
disease
rare
fatal
pediatric
neurodegenerative
lysosomal
storage
disorder
lsd
resulting
deficiencies
key
enzyme
lysosome
genetic
defects
lead
toxic
accumulation
gangliosides
resulting
neurodegeneration
life
expectancy
shortened
two
four
years
age
fda
defines
rare
pediatric
disease
serious
disease
disease
manifestations
primarily
affect
individuals
aged
birth
years
pediatric
diseases
recognized
rare
affect
people
united
states
investigational
gene
therapy
sandhoff
disease
rare
fatal
pediatric
neurodegenerative
genetic
disorders
within
gangliosidosis
family
caused
defects
hexa
leading
disease
hexb
leading
sandhoff
disease
genes
encode
two
subunits
hexa
enzyme
forms
gangliosidosis
caused
overwhelming
storage
ganglioside
within
neurons
throughout
central
nervous
system
normally
degraded
lysosome
isozyme
hexa
genetic
defects
lead
progressive
neurodegeneration
shortened
life
expectancy
aims
restore
hexa
levels
introducing
functional
copy
hexa
hexb
genes
via
delivery
two
vectors
axovant
licensed
exclusive
worldwide
rights
university
massachusetts
medical
school
development
commercialization
gene
therapy
programs
gangliosidosis
gangliosidosis
including
sandhoff
diseases
axovant
gene
therapies
axovant
gene
therapies
gene
therapy
company
focused
developing
pipeline
innovative
product
candidates
debilitating
neurodegenerative
diseases
current
pipeline
gene
therapy
candidates
targets
gangliosidosis
gangliosidosis
also
known
disease
sandhoff
disease
parkinson
disease
axovant
focused
accelerating
product
candidates
clinical
trials
team
experts
gene
therapy
development
external
partnerships
leading
gene
therapy
organizations
information
visit
statements
press
release
contains
statements
purposes
safe
harbor
provisions
private
securities
litigation
reform
act
federal
securities
laws
use
words
intended
may
might
would
expect
believe
estimate
similar
expressions
intended
identify
statements
example
statements
axovant
makes
regarding
costs
associated
operating
activities
statements
based
estimates
assumptions
axovant
management
although
axovant
believes
reasonable
inherently
uncertain
statements
subject
risks
uncertainties
may
cause
actual
results
differ
materially
axovant
expected
risks
uncertainties
include
among
others
impact
pandemic
operations
initiation
conduct
preclinical
studies
clinical
trials
availability
data
clinical
trials
scaling
manufacturing
expectations
regulatory
submissions
approvals
continued
development
gene
therapy
product
candidates
platforms
axovant
scientific
approach
general
development
progress
availability
commercial
potential
axovant
product
candidates
statements
also
subject
number
material
risks
uncertainties
described
axovant
recent
quarterly
report
form
filed
securities
exchange
commission
august
updated
subsequent
filings
securities
exchange
commission
statement
speaks
date
made
axovant
undertakes
obligation
publicly
update
revise
statement
whether
result
new
information
future
events
otherwise
contacts
media
investors
josephine
belluardo
lifesci
communications
jo
media
parag
meswani
axovant
gene
therapies
investors
